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ABSTRACT
Context: Treatment of advanced and recurrent endometrial cancer (EC) is still an 
unmet need for oncologists and gynecologic oncologists. The Cancer Genome Atlas 
Research Network (TCGA) recently provided a new genomic classification, dividing 
EC in four subgroups. Two types of EC, the polymerase epsilon (POLE)-ultra-mutated 
and the microsatellite instability-hyper-mutated (MSI-H), are characterized by a high 
mutation rate providing the rationale for a potential activity of checkpoint inhibitors.
Materials and Methods: We analyzed all available evidence supporting the role of 
tumor microenvironment (TME) in EC development and the therapeutic implications 
offered by immune checkpoint inhibitors in this setting. We performed a review on 
Pubmed with Mesh keywords ‘endometrial cancer’ and the name of each checkpoint 
inhibitor discussed in the article. The same search was operated on clinicaltrial.
gov to identify ongoing clinical trials exploring PD-1/PD-L1 and CTLA-4 axis in EC, 
particularly focusing on POLE-ultra-muted and MSI-H cancer types.
Results: POLE-ultra-mutated and MSI-H ECs showed an active TME expressing 
high number of neo-antigens and an elevated amount of tumor infiltrating lymphocytes 
(TILs). Preliminary results from a phase-1 clinical trial (KEYNOTE-028) demonstrated 
antitumor activity of Pembrolizumab in EC. Moreover, both Pembrolizumab and 
Nivolumab reported durable clinical responses in POLE-ultra-mutated patients.
Conclusions: Immune checkpoint inhibitors are an attractive option in POLE-
ultra-mutated and MSI-H ECs. Future investigations in these subgroups include 
combinations of checkpoints inhibitors with chemotherapy and small tyrosine kinase 
inhibitors (TKIs) to enhance a more robust intra-tumoral immune response.
INTRODUCTION
Endometrial Cancer (EC) is expected to be the 
4th most common malignancy among women and the 
6th leading cause of death in 2017 [1]. EC is frequently 
associated with Lynch Syndrome (LS). also called 
hereditary non-polyposis colon cancer (HNPCC), [2], an 
autosomal dominant genetic disorder which confers an 
increased risk of developing different kind of tumours, [3]. 
LS , is characterized by alterations in genes 
involved in DNA mismatch repair (MMR), such 
as MLH1, MSH2, MSH6, PMS2 and EPCAM, 
resulting in microsatellite instability (MSI) [4]. 
For the 67% of EC patients diagnosed at an early stage, 
5-year overall survival is of 95% after surgery with or 
without radiotherapy. Instead EC patients diagnosed at a 
late stage have a 5-year survival rate of only 17% [1, 5]; 
these patients are candidate to systemic treatment with 
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palliative intent, including chemotherapy, among which 
carboplatin-paclitaxel doublet is the most effective scheme 
[1], and endocrine treatments [6]. Up to date there is no 
standard second line therapy [7].
In this review, we will concentrate on the scientific 
background supporting the clinical development of 
immune checkpoint inhibitors in advanced and recurrent 
disease with a specific focus on the role of tumor 
microenvironment (TME).
The “modern” molecular classification: beyond 
Bokhman’s dual scheme 
EC is an heterogeneous disease with various 
histological subtypes, which have different pathogenesis, 
prognosis and sensitivity to different therapeutic agents [8].
In the past decades, EC has been classified in two 
subtypes, respectively named Type I and Type II according 
to Bokhman’s model [9], based on clinical characteristics 
integrated with histological features and hormone receptor 
(HR) status. Type I is the most common EC (60–70% of 
cases); it includes grade1 and 2 endometrioid cancer with a 
high presence of Estrogen Receptors (ERs) and Progesteron 
Receptors (PgRs). It is related to increased Estrogen levels 
and endometrial hyperplasia and it is usually associated with 
a good prognosis (median 5-year survival rates of 85.6%). 
The most frequently altered pathway in Type I is PTEN-
PIK3/AKT/mTOR (PTEN is mutated in approximately 52–
78% of lesions), followed by KRAS mutations (15–43%), 
ARID1A and Β-catenin alterations [10]. MSI is present in 
one third of type I EC [11].
Type II EC comprises Grade 3 endometrioid, 
serous or clear cell HR negative cancers, and it is usually 
associated with endometrial atrophy [12]. TP53 is the 
hallmark alteration of this subtype. Patients with type II 
EC generally show an advanced stage at diagnosis, a low 
response rate to therapies and a poor prognosis [11, 12].
This dualistic model has recently been expanded 
in consideration of new knowledge concerning genomic 
and transcriptomic analysis [13, 14]. In 2013 TGCA (The 
Cancer Genome Atlas Research Network) [14] published 
the first genomic characterisation of EC. Results of this 
study allowed EC classification in four different subtypes, 
based on somatic mutations, copy number alterations and 
microsatellite instability:
POLE-ultra-mutated malignancies, representing 
6.4% of low-grade and 17.4% of high-grade endometrioid 
tumours, are characterized by a high mutation rate 
(232 × 10–6 mutations/Mb); their hallmarks are somatic 
mutations in the exonuclease domain of POLE that 
encodes the catalytic subunit of DNA polymerase 
epsilon. Loss of function of this polymerase, which plays 
a relevant role in DNA repair, leads to a high frequency 
of C>A transversions, few copy number alteration and 
microsatellite stability (MSS). PTEN, PIK3R1, PIK3CA, 
RAS are frequently mutated [12, 14, 15]. Despite the 
histological grade, this group is associated with good 
prognosis [16–20].
MSI-hyper-mutated (MSI-H) tumors represent 
28.6% of low grade and 54.3% of high-grade endometrioid 
EC [14, 15, 21]. They show MSI and high mutation rate 
(18 × 10−6 mutations/Mb) related to defects in MMR 
system (the most implicated genes are MLH1, MSH2, 
MSH6, PMS2), both in sporadic and hereditary EC. 
PTEN mutations and subsequent alterations of the PTEN-
PIK3CA pathway recur in this subgroup [22]. Further 
genetic abnormalities are frequent, like RPL22 frameshift 
deletions and KRAS mutation. There is no significant 
correlation between MSI and outcome in ECs patients [23].
Copy-number low EC is characterized by a low 
mutation rate (2.9 × 10–6 mutations/Mb) and MSS. It is 
frequently a low-grade endometrioid cancer (in TGCA 
60%of low-grade and only 8.7% of high grade EC were 
MSS copy low); PTEN and PIK3CA are mutated in 77% 
and 53% of cases respectively [14, 15]. Other common 
alterations involve WNT-B catenin axis; RAS mutation 
is rare; PgR levels are high and this finding predicts 
usefulness of endocrine therapy [21, 24]. Prognosis is 
similar to MSI-H tumors without a clear correlation 
between this subtype and clinical outcome.
Copy-number high serous like subgroup includes 
mainly serous and mixed histology tumors with some 
high grade endometrioid EC. It has a low mutation rate 
(2.3 × 10−6 mutations/Mb) and a small load of copy 
number aberrations. TP53 is commonly mutated (92%), 
whereas KRAS and PTEN mutation are infrequent; 25% 
of the serous-like tumours are ERBB2-amplified [14, 21]. 
Prognosis of these patients is poor [12, 15].
This new classification, reported in Figure 1, could 
be comparable to the already well known pathogenesis 
model of colon-rectal cancer [25] and may represent a 
step forward in defining prognosis of EC patients and may 
help in improving clinical trial design with targeted agents 
[24, 26, 27].
As recently reported, normal endometrium has a 
peculiar immune system; indeed, it has a dualistic role: 
it should be active against sexual pathogens and should 
allow the growth of an allogenic and “non-self” fetus 
[28, 29]. This behavior is regulated by sex hormones 
that influence therefore the TME, especially defining the 
typology of adaptive immune cells [30]. 
It is well known that immune cells can recognize 
and eliminate cancer cells through the identification of 
tumor –specific antigens (TSA) and tumor-associated 
antigens (TAA) [31].
Physiologically, when TAA are recognized by T 
cells they are handled, converted into small fragments 
and finally presented by antigen-presenting cells (APCs) 
after loading on major histocompatibility complex (MHC) 
class I and II. Usually, immune response activation is 
elicited if two positive signals are present. The first one 
is the interaction between MHC molecules and T cell 
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receptors (TCR); the second one is the connection of 
the co-stimulatory receptor CD28, present on T cells’ 
surface, with its ligand B7 on APCs. In order to avoid 
autoimmune reaction CD28 has a competitor for binding 
B7, the cytotoxic T lymphocyte antigen-4 (CTLA-4), 
which carries an inhibitory signal. This negative feedback 
is mostly represented within secondary lymphoid organs, 
while the inhibitory pathway more frequently present 
within peripheral TME is the connection between the 
programmed cell death-1 (PD-1) receptor on the T 
cells, and the programmed cell death ligand-1 and 2 
(PD-L1 and PD-L2) on the tumor cells surface [32, 33]. 
Different molecular patterns are involved downstream 
this interaction, such as inhibition of PI3K/AKT and Ras/
MEK/Erk pathways, through down-regulation of PTEN 
and PLC-γ1 respectively [34–36] (Figure 2). Inflammatory 
cytokines, as interferon, IL-4 and IL-10, generated after 
recognition of TAA and TSA stimulates PD-1 and PD-
L1 over-expression, lead to down-regulation of T-cell 
reaction and create the mechanism called “adaptive 
immune resistance” [37]. Other immune checkpoints 
seem to play a role in adaptive immune resistance, such as 
Lymphocyte Activation Gene 3 (LAG-3) and indoleamine 
2,3-dioxygenase (IDO), both up-regulated in POLE and 
MSI-H subtypes [38, 39]. Among gynecological cancer, 
EC show the highest expression of PD-1 and PD-L1,75 % 
and 25–100% respectively [40]. Moreover, Vanderstraeten 
and coll. analyzed other immune-related molecules and 
reported that B7-H4, responsible of another inhibitory 
pathway of CD4+ and CD8+ T cells, is present in 90% of 
EC specimens, while IDO is expressed only in 21% of 
EC samples [39]. These findings confirm an important role 
of PD-1/PD-L1 pathway and suggest B7-H4 signal as a 
potential new therapeutic target.
The correlation between PD-L1 expression and 
patient’s outcome is controversial, since has been 
associated with a worse prognosis in some tumors, 
like non-small cell lung cancer (NSCLC) [41], kidney 
[42–44] and bladder [45] cancer, and with a good one in 
melanoma [46]. Currently, PD-L1 is routinely analyzed 
in advanced NSCLC in order to prescribe checkpoint 
inhibitors, even if is still controversial which is the best 
cut-off to define positivity and which the best antibody 
to detect the expression on immunohistochemistry (IHC) 
assay [47]. PD-L1 detection is regularly used also in the 
treatment of kidney and bladder cancers [48].
The prognostic value of the expression of this 
inhibitory pathway, as the role of other components of 
tumor microenvironment (TME), such as tumor infiltrating 
lymphocytes (TILs), is currently under investigation in 
EC. PD-1 and PD-L1 are more frequently reported in 
POLE-mutated and MSI-H tumors. This pathway might 
account for more aggressive histopathologic features 
observed in POLE-mutated, as reported above, even if 
these tumors have a good prognosis related to a higher 
number of CD3+ and CD8+ TILs that prevent disease 
dissemination [49, 50]. POLE-mutated and MSI tumors 
have an active TME not only for the high number of 
TILs, but also for the huge amount of tumor specific 
neo-antigens, generated by genetic alteration acquired 
due to impaired DNA replication fidelity (POLE) and 
defective DNA MMR system (MSI-H) [4, 14] (Figure 3). 
Recent studies have characterized the different cell 
populations constituting TME. The presence of TILs 
Figure 1: Shows the ECs classification according to TGCA including the most common genetic alteration in each 
subtype. POLE: polymerase epsilon; MMR:mismatch repair; p53: tumor protein p53; PTEN: phosphatase and tensin homolog; PIK3: 
phosphatidylinositol-4,5-bisphosphate 3 kinase; KRAS: Kirsten rat sarcoma viral oncogene homolog; MMS: microsatellite stability; MSI: 
microsatellite instability; MLH: mutL homolog 1; MSH2: mutS homolg 2; MSH6: mutS homolog 6; RPL22: 60S ribosomal protein L22; 
ERBB2: human receptor tyrosine-protein kinase erbB-2; WNT-B: WNT-beta catenin pathway; PgR: progesteron receptor.
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appears associated with a better outcome in many 
different kinds of cancers such as melanoma [51], 
esophageal [52], breast [53], colorectal [54] and ovarian 
cancer [55, 56]. In EC, in 2009 de Jong and colleagues 
assessed the number of CD8+ (cytotoxic T-lymphocytes, 
CTL), FOXP3+ (regulatory T-lymphocytes, Treg) and 
CD45R0+ (memory T-lymphocytes) TILs by IHCon tissue 
microarrays [57]. High numbers of CTL and a high CD8+/ 
FOXP3+ ratio were correlated with a longer disease free 
survival (DFS), while high levels of CTL and presence 
of CD45R0+ memory cells were associated with a greater 
overall survival (OS). In the multivariate analyses high 
presence of CTL was an independent prognostic factor 
for longer OS in the entire EC population (HR 0.48, 
Figure 3: Shows proteins involved in DNA mismatch repair system and the formation of neoantigens resulting from 
their deficiency. TAA: tumor associated antigen.
Figure 2: Shows the interactions of PD-1 and CTLA-4 expressed on the surface of the T cells with the respective 
ligands and the subsequent activation of immune checkpoint signalling pathways that inhibit lymphocytes survival and 
proliferation. CTLA-4:Cytotoxic T-Lymphocyte Antigen 4; MHC: Major histocompatibility complex; MMR: Mismatch repair PD-1: 
Programmed cell death protein 1; PD-L1: Programmed death-ligand 1; TAA: Tumor associated antigen ;TCR: T-cell receptor.
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p = 0.019), with a major impact in type II EC (HR 0.17, 
p < 0.001), whereas high CD8+/ FOXP3+ ratio is the factor 
independently correlated with prolonged survival in type 
I cancers. The prognostic role of CD8+/ FOXP3+ ratio 
was confirmed also by subsequent investigations [58, 59]. 
The studies focused on Treg alone reported a correlation 
with tumor stage, grade and myometrial invasion but not 
with survival [60, 61]. Recently, Pakish and colleagues 
evaluated the EC TME matching and comparing MSI-H 
with MSS (POLE-mutant cases and cases with unknown 
POLE status were excluded) [4]. They reported an 
increased number of immune cells in specimens from 
MSI-H EC including granzyme B+ cells, activated CTL 
and PD-L1 + cells. The authors also compared sporadic 
MSI-H EC with those related to LS (LS MSI-H): they 
observed an increased level of CD8+ cells and activated 
CTL with a lower number of macrophages in stroma of 
LS MSI-H EC while sporadic MSI-H EC showed a higher 
level of PD-L1 + macrophages. The analyses performed 
by the TransPORTEC consortium on 116 high-risk ECs, 
published also in 2017, confirmed that POLE-mutant and 
MSI-H tumors are characterized by higher numbers of 
tumor-infiltrating T cells. These two subgroups are both 
neoantigen-rich and with a huge density of PD-1 and 
PD-L1 expression and so are the perfect candidates for 
immune checkpoint inhibitors, as further reported [62]. In 
order to avoid the activation of the inhibitory pathways 
described above different antibodies have been developed, 
targeting PD-1, PD-L1, PD-L2 and CTLA-4 These 
molecules, known as “checkpoint inhibitors”, exhibited 
efficacy and durable clinical response in various cancer 
types and have already been approved for NSCLC 
[63, 64], melanoma [46, 65–69], kidney [70], bladder 
[71, 72] and Hodgkin Lymphoma [73, 74]. 
Clinical activity of checkpoint inhibitors in 
endometrial cancer
The first evidence for clinical activity of 
immunotherapy in EC derive from a phase II trial 
published in 2015 by Le and colleagues which enrolled 
41 patients [75]. Study population was divided in three 
cohorts, including respectively patients with MMR-
deficient colorectal cancer, patients with MMR proficient 
colorectal cancer and patients with MMR-deficient 
cancers other than colorectal cancer; in third cohort were 
also included two patients affected by EC. All patients 
were treated with the anti-PD-1 Pembrolizumab. Authors 
reported a higher immune-related objective response 
rate (ORR) and 20-week immune related progression 
free survival (PFS), 40% and 78%, respectively, in the 
MMR deficiency cohorts, versus 0% and 11% in MMR 
proficient colorectal patients. In cohort C, including the 
2 EC patients, immune-related ORR and PFS were 71% 
and 67%, respectively. This is a pivotal study reporting 
for the first time a connection between TME, genotype 
and response to checkpoint inhibitors, a significant step 
forward in the identification of predictors of response, as 
discussed in the next section.
Recently, Ott and colleagues published the results 
of KEYNOTE-028 trial, a phase Ib study involving 24 
patients with advanced EC [76]. All patients were treated 
with Pembrolizumab 10 mg/kg every two weeks for up 
to 24 months or until confirmed progression, intolerable 
toxicity, death, or consent withdrawal. Overall Response 
rate observed was 13%. Three patients obtained a partial 
response and other three achieved a stable disease. 
Authors reported a six-months PFS and OS rates of 
19.0% and 68.8% respectively. Drug-related adverse 
events occurred in 54.2% of patients; most common were 
pruritus, asthenia, fatigue, pyrexia, and decreased appetite. 
No patients died or discontinued Pembrolizumab because 
of toxicities. Interestingly, Ganesan and collegues reported 
the case of a durable partial response with Pembrolizumab 
in one patient with POLE-mutation [77]. Pembrolizumab 
has been tested in metastatic EC also in combination with 
Lenvatinib, a multikinase-inhibitor with antiangiogenic 
activity. Makker and colleagues recently presented the 
results of a phase I / II trial in which 23 patients received 
Lenvatinib 20 mg/day and Pembrolizumab 200 mg every 
three weeks. The authors reported an ORR of 48% and 
a DCR of 96%. The most common adverse events were 
hypertension, fatigue, arthralgia, diarrhea and nausea [78]. 
In 2016 Santin and colleagues reported the cases 
of two patients with recurrent EC refractory to surgery, 
chemotherapy and radiotherapy treated with the anti-
PD-1 Nivolumab [79]. The two women were respectively 
affected by a mixed clear cell and endometrioid POLE 
mutated EC and by a serous MSH6 mutated EC. Both 
patients were treated with Nivolumab 3 mg/kg biweekly. 
CTL infiltration and PD-L1 expression were evaluated on 
a pretreatment biopsy. The first patient showed a moderate 
amount of peri and intratumoral lymphocytic infiltrate. 
Moreover, a weak membranous PD-L1 expression was 
reported in about 5% of the tumor cells, whereas the peri- 
and intratumoral lymphocytes were PD-L1 negative. In 
the second patient the peri-tumoral lymphocytic infiltrate 
was moderate, whereas there were fewer CD8-positive 
lymphocytes within the tumor cell nests. PD-L1 was 
observed in approximately20% of peri- and intratumoral 
lymphocytes, while no significant PD-L1 expression was 
observed for cancer cells. In this case authors evaluated 
also p53 expression by immune histochemistry which 
revealed a wild type pattern. Both patients obtained a 
persistent clinical response to Nivolumab confirmed by a 
CT scan respectively at 7 and 9 months from the start of 
immunotherapy. No severe toxicities were reported.
Antibodies against PD-L1 were also tested for the 
treatment of endometrial carcinoma.
Fleming and colleagues reported the results of 
a phase Ia study in which 15 women with EC received 
Atezolizumab 15 mg/m 2 every three weeks. The majority 
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of patients were MSS (7/15) or MSI unknown ( 7/1), only 
one patient has a MSI-H disease. Authors also evaluated 
the status of PD-L1: 33% of patients had an expression 
of PD-L1 greater than 5% on immune cells while in the 
remaining 67% the PD-L1 expression was lower. Two 
patients obtained a partial response and other two achieved 
a stable disease with an ORR of 13% and a DCR of 27%. 
Both responders had an expression of PD-L1 greater than 
5 %, one had MSS disease heavily infiltrated with TILs, 
the other had a MSI-H disease, moderately infiltrated with 
TILs. Duration of response was 7.3 and 8.1+ months, 
respectively. Authors reported a median PFS of 1.7 months 
and a median OS of 9.6 months. Drug related severe 
adverse events (colitis and rash) occurred only in two 
patients, no G4-5 related AEs were reported [80] A Phase 2 
study with an anti-PD-L1 antibody was recently presented 
at ASCO 2017: it is an open-label, two stage trial in which 
Avelumab 10 mg/kg was administered biweekly to women 
with recurrent or persistent endometrial cancer. Patients 
were divided in two cohorts on the basis of the MMR 
proteins expression. In the first stage, 16 patients will be 
enrolled in each cohort, if at least two objective responses 
or two PFS at six months were observed accrual will 
continue to the second stage. The trial is ongoing and until 
now 16 patients have been enrolled: 13 in the MSS cohort 
and 3 in the MSI/POLE cohort. Co-primary endpoints are 
ORR and rate of PFS at six months [81]. The results of the 
preliminary clinical data are summarized in Table 1.
As discussed above another possible target for 
checkpoint inhibitors is CTLA-4, in order to prevent 
binding with its ligand B7. Ipilimumab and Tremelimumab 
are monoclonal antibodies able to disrupt this interaction. 
This approach has proven to be effective in the treatment 
of melanoma [82, 83], but data supporting the effectiveness 
of anti-CTLA4 in the treatment of EC have not been 
reported so far.
DISCUSSION AND FUTURE PERSPECTIVES
The use of checkpoint inhibitors has a strong 
rationale in EC, however clinical development is at very 
beginning and, despite preliminary encouraging results, 
several issues need to be addressed. 
First of all, few data are available regarding predictive 
biomarkers of response to checkpoint inhibitors. In order to 
select patients who mostly benefit from these therapies more 
and more studies analyze cancer genome and its correlation 
with TME. PD-L1 expression level has been reported as a 
predictive biomarker of response in NSCLC [63, 65] but 
its predictive role is not consistent across different cancers 
types. This may be related to various detection strategies 
and different specimens analyzed (before, during or after 
treatments) [66]. Moreover, a crucial role in immune 
surveillance is played by the others cells expressing PD-
L1 present in TME, as reported in a translational study by 
Webb and colleagues for tumor-associated macrophages 
(TAMs) on the basis of tissue microarrays of optimally 
debulked ovarian cancers [84]. 
Recently, huge progress has been achieved regarding 
the relationship between cancer genome and response to 
checkpoint inhibitors [85, 86]. A relationship between 
response to PD-1/PDL-1 inhibitors and somatic mutations 
load has been reported in melanoma and lung cancer 
[67, 68] according to the hypothesis that identifying 
neo-antigens generated by mutations is an essential 
step for immune response. Indeed, mutational burden 
defines immunogenicity of cancers [87, 88]. Besides the 
neo-antigens loads, some studies were conducted in the 
melanoma to identify mechanisms related to resistance to 
PD-1 inhibitors. Shin and colleagues found that loss of 
function mutations in JAK1 and JAK2, where associated 
with a deficiency of interferons that physiologically induce 
PD-L1 upregulation, in several melanoma cells lines 
which correlate to resistance to checkpoints inhibitors. 
Moreover, they reported beta-2 microglobulin deletions 
or mutations leading to beta-2 microglobulin inactivation 
and subsequent inability for T cells to recognize the 
tumor. These mutations are responsible for primary 
resistance or can be developed during treatment, arising 
secondary resistance to checkpoints inhibitors [89, 90]. 
The importance of the interferon associated pathways for 
the response to anti PD-1 and CTLA-4 was confirmed also 
by an MD Anderson report [91].
As reported above, two subgroups of EC, POLE-
ultra-mutated and MSI-H, are characterized by higher 
number of neo-antigens and the elevated amount of 
TILs [15]. The consequent high immunogenicity of POLE-
ultramutated EC is speculated to be responsible for the 
good prognosis and possibly for likelihood of responding to 
immune checkpoint inhibitors [92]. Neo-antigen load could 
possibly be a biomarker of response also in hypomutated 
EC, as reported by Shukla and colleagues [93]. Indeed 
they observed that hypo-mutated tumors with highest neo-
antigen load have a better PFS. Moreover, they reported that 
a lower neo-antigens number is associated with particular 
gene alterations, CTNNB1 and PIK3CA mutations and 
MYC amplifications. The above variations could be used 
as indicators of less immunogenicity and, consequently, 
of lower response rate to checkpoint inhibitors.These 
discoveries could help clinicians to identify EC patients 
that could benefit from checkpoint inhibitors.
The need to identify possible biomarkers of response 
is also crucial for the ongoing clinical trials, reported in 
Table 2, which, following evidence derived from other 
cancers, are exploring combinations of checkpoints 
inhibitors or associations of checkpoints inhibitors with 
chemotherapy, small tyrosine kinase inhibitors (TKIs) and 
mTOR inhibitors.
The study published by Pakish evaluating the 
immune infiltrate in MSI-H EC suggests for the first time 
Oncotarget90538www.impactjournals.com/oncotarget
that among patients with MSI, there may be differences 
in the TME on the basis of hereditary or sporadic 
nature of the MMR deficiency [4]. These data have 
been recently confirmed at the Society for Gynecologic 
Oncology Annual Meeting on Women’s Cancer by Ring 
and colleagues, who reported that EC related to LS has a 
stronger expression of PD-L1, in particular for LS caused 
by MSH6 loss [94].
For this reason, future clinical trials should stratify 
patients considering Lynch related and sporadic MSI-H 
tumor.
More recently, the European Society of Medical 
Oncology (ESMO) provided a practical guidance for 
MMR-deficiency testing in EC [95] underlying its 
emerging importance both to guide adjuvant treatment 
and to identify LS cases. Although there is not a general 
agreement on testing EC patients for LS, the above data 
suggest that MMR-deficiency could be predictive of 
response to immunotherapy and help clinicians in their 
therapeutic choices. At present, both MSI (pentaplex 
panel) and IHC are validated methods in EC testing 
[96, 97]. 
Clinical settings and associations
Considering its important role in EC, one of 
the most promising partners of checkpoint inhibitors 
is radiotherapy. In particular, as suggested for other 
malignancies, the so called out-of-the-field (abscopal) 
responses in patients receiving radiation therapy during 
immunotherapy may be relevant also in EC [98]. Another 
important direction of clinical research is represented by 
the association of chemotherapy and immune checkpoint 
inhibitors [99]. Although chemotherapies are believed 
to be immunosuppressive, when given at the right dose 
and sequence may provide a “priming” effect for the 
immune system. Trials have shown already that platinum 
based chemotherapy associated with immune checkpoint 
inhibitors is active in NSCLC [100]. Since chemotherapy 
(especially platinum based chemotherapy) is also active in 
EC, it is likely to obtain similar results with the addition of 
a checkpoint inhibitor.
Considering other malignancies where the 
development of immune checkpoint inhibitors is more 
advanced (e.g. melanoma), there is no clear evidence 
Table 1: Published and preliminary data of trials evaluating the activity of checkpoint inhibitors 





Class of experimental 
agent
Line of therapy ORR PFS OS Study name/First author
Pembrolizumab 10 mg/kg every 2 weeks 24 Ib Anti-PD-1 2L+ 13% 19% at six months 68.8% at six months KEYNOTE-028
Lenvatinib 20 mg/day + Pembrolizumab 
200 mg every 3 weeks 23 Ib/II
Multikinase inhibitor + 
Anti-PD-1 2L+ 48% Not estimable Not estimable Vicky Makker
Atezolizumab 1200 mg or 15 mg/kg 
IV q3w 15 Ia Anti-PD-L1 2L+ 13% 1.7 months 9.6 months Gini F. Fleming
PFS = Progression Free Survival; ORR = Overall Response Rate; OS = Overall Survival.
Table 2: Ongoing trialsusing checkpoint inhibitors in endometrial cancer
Combination Treatment setting Line of therapy Phase Primaryendpoint Status Trial identifer
aPD-L1 Avelumab in Patients With MSS, MSI-H and POLE-mutated 2L+ 2 PFS6 Recruiting NCT02912572
aPD-1 Pembrolizumab in Ultramutated and Hypermutated EC 2L+ 2 ORR, safety by CTCAE v4 Recruiting NCT02899793
aPD-1 Pembrolizumab on the TumoralImmunoprofile of Gynecologic Cancers 1L 1 Tumor immune infiltrates Recruiting NCT02728830
aPD-1 MK-3475 Immunotherapy in Endometrial Carcinoma 1L 1 Safety by CTCAE v4 Recruiting NCT02630823
aPD-1 + Chemo Pembro/Carbo/Taxol 1L+ 2 ORR Not yet recruiting NCT02549209
aPD-1 + Bev/C/PLD IMGN853 + Bevacizumab, Carboplatin, PLD or Pembrolizumab 2L+ 1 ORR, SAEs, TEAEs Recruiting NCT02606305
aPD-1 + TKI Pembrolizumab + Lenvatinib 2L+ 1b/2 MTD, DLTs, ORR Recruiting NCT02501096
aPD-1 + TIL Pembrolizubab+ TIL PBL and aldesleukin 2L+ 2 ORR Recruiting NCT01174121
aPD-1 + TKI Pembrolizumab +Itacitinib 2L+ 1 Safety by CTCAE v4 Recruiting NCT02646748
aPD-L1 + aCTLA-4 Durvalumab +/− Tremelimumab 2L+ 2 ORR Recruiting NCT03015129
aPD-1 + Chemo Nivolumab + Chemotherapy 2L+ 1b/2 RP2D Recruiting NCT02423954
aPD-1 + aCTLA-4 Nivolumab + Ipilimumab 2L+ 2 ORR Not yet recruiting NCT02982486
aPD-1 + mTORi Nivolumab + Temsirolimus/ Nivolumab + CT 2L+ 1b/2 RP2D Recruiting NCT02423954
aPD-1 + aCTLA-4 Nivolumab + Ipilimumab in rare tumors 1L+ 2 ORR Recruiting NCT02834013
aPD-L1 + Chemo Atezolizumab + Carboplatin-cyclophosphamide 2L 1 Toxicity by CTCAE v4 Recruiting NCT02914470
aPD-L1 + IDO Inhibithor Atezolizumab + GDC-0919 2L+ 1 DLT, SAEs Recruiting NCT02471846
Chemo, chemotherapy; Bev, bevacizumab; C, Carboplatin; PLD, pegylatedliposomaldoxorubicin; TKI, tyrosine-kinaseinhibitor; TIL, tumorinfiltratinglymphocytes; mTORi, mTORinhibitor; IDO, indoleamine 
2,3-dioxigenase; L, line (regime of chemotherapy); PFS6, progression free survivalat 6 months;ORR, overallresponse rate; CTCAE v4, Common TerminologyCriteria for AdverseEvents, version 4.03; SAEs, 
seriousadverseevents; TEAEs, treatment-emergentadverseevents; MTD,maximum tolerated dose; DLT, dose-limitingtoxicities; RP2D, recommendedphase 2 dose; NCT, National Clinical Trial.
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suggesting a significant improvement in survival [69]. 
Accordingly, it is therefore more likely that patients with 
advanced endometrial cancer (stage III and IV) may 
benefit best from immune checkpoint inhibitors. 
CONCLUSIONS
ECs have already proved to be an immunogenic 
diseases suggesting a potential role for checkpoints 
inhibitors in their treatment. As reviewed above, the TCGA 
classification is a step forward towards individualized 
therapies and should be considered in future clinical trials, 
to assess which subsets of EC patients are more likely to 
benefit from an immunotherapeutic approach. Further 
investigations should include the identification of which 
dominant immunosuppressive pathway characterizes each 
subtype in order to better identify reliable biomarkers of 
response. Future strategies will explore different clinical 
settings and combinations of chemo and radiotherapy 
with checkpoint inhibitors to boost immune response and 
improve patients outcomes. 
MATERIALS AND METHODS
Search strategy
We conducted a search on Medline with Mesh 
keywords: endometrial cancer, endometrial carcinoma, 
endometrial neoplasm, endometrium cancer, endometrium 
carcinoma, and endometrium neoplasm. Moreover, the search 
strategy included terms for endometrial cancer matched 
with immunotherapy; tumor infiltrating lymphocytes 
(TILs); polymerase epsilon (POLE)-ultra-mutated; 
microsatellite instability (MSI); tumor-microenvironment; 
programmed death-1 (PD-1); programmed death-ligand 1 
(PD-L1);cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4); the name of all checkpoint inhibitors discussed 
in the paper. The literature search was performed up to June 
2017. Moreover had searched abstract books of conference 
proceedings between 2010 and 2017 to identify potentially 
eligible studies. With the same keywords we operated a 
search on clinicaltrials.gov.
Selection criteria 
Retrevied articles were examined by all coauthors to 
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